Cardiome Pharma Corp. (CRME)
-NasdaqCM 1.94 0.00(0.00%) May 24, 3:59PM EDT
| Prev Close: | 1.94 |
|---|
| Open: | 1.97 |
|---|
| Bid: | N/A |
|---|
| Ask: | 2.50 x 15200 |
|---|
| 1y Target Est: | 3.63 |
|---|
| Beta: | 1.34 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 1.93 - 2.00 |
|---|
| 52wk Range: | 1.20 - 2.70 |
|---|
| Volume: | 27,120 |
|---|
| Avg Vol (3m): | 76,952 |
|---|
| Market Cap: | 24.19M |
|---|
| P/E (ttm): | 3.44 |
|---|
| EPS (ttm): | 0.56 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Cardiome Pharma Management Discusses Q1 2013 Results - Earnings Call Transcriptat Seeking Alpha(Mon, May 13)
- Cardiome Reports First Quarter ResultsCNW Group(Mon, May 13)
- Cardiome Reports First Quarter ResultsPR Newswire(Mon, May 13)
- Cardiome To Present At Bloom Burton & Co. Healthcare Investor ConferenceCNW Group(Fri, May 10)
- Cardiome To Present At Bloom Burton & Co. Healthcare Investor ConferencePR Newswire(Fri, May 10)
- Cardiome to Hold First Quarter 2013 Financial Results Conference Call on May 13CNW Group(Thu, May 9)
- Cardiome Accepts the Transfer of Sponsorship of U.S. and Canadian Vernakalant IV and Oral Regulatory Filings from MerckCNW Group(Thu, May 2)
- Cardiome Announces Worldwide Sales And Marketing Of BRINAVESS™CNW Group(Thu, Apr 25)
- CARDIOME PHARMA CORP FinancialsEDGAR Online Financials(Wed, Apr 17)
- Cardiome Announces Share Consolidation Effective April 12, 2013CNW Group(Fri, Apr 12)
- Cardiome Announces Shareholder Approval of Share ConsolidationCNW Group(Thu, Apr 4)
- Cardiome Appoints Jürgen Polifka, Ph.D., as General Manager, Sales and Marketing EuropeCNW Group(Tue, Apr 2)
- Cardiome Announces The Addition Of Dr. Steen Juul-Möller As Medical Director, EuropePR Newswire(Thu, Mar 28)
- Cardiome Announces The Addition Of Dr. Steen Juul-Möller As Medical Director, EuropeCNW Group(Thu, Mar 28)
- Cardiome Announces Changes to Senior Management TeamPR Newswire(Tue, Mar 26)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 58.15 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.58 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.19 |
|---|
| Mean Recommendation*: | 3.3 |
|---|
| PEG Ratio (5 yr expected): | -0.12 |
|---|
Business Summary
Cardiome Pharma Corp., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies that enhance the health of patients.
View More 
0.06%